Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma

BACKGROUND: The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients. METHODS: Between 2003 a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Chin J Cancer Res
Главные авторы: Jia, Bo, Shi, Yuankai, Kang, Suyi, Yang, Sheng, Hu, Shaoxuan, Li, Yexiong, Dong, Mei, Wang, Weihu, Yang, Jianliang, Zhou, Liqiang, Liu, Peng, Zhou, Shengyu, Qin, Yan, Gui, Lin, Zhang, Changgong, Lin, Hua, Chen, Shanshan, Wang, Lin, He, Xiaohui
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2015
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4626815/
https://ncbi.nlm.nih.gov/pubmed/26543339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2015.10.04
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы